|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hayes DN, Monti S, Parmigiani G, Gilks CB,
Naoki K, Bhattacharjee A, Socinski MA, Perou C and Meyerson M: Gene
expression profiling reveals reproducible human lung adenocarcinoma
subtypes in multiple independent patient cohorts. J Clin Oncol.
24:5079–5090. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ramalingam S and Belani C: Systemic
chemotherapy for advanced non-small cell lung cancer: Recent
advances and future directions. Oncologist. 13 Suppl 1:5–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Heymach JV and Lippman SM: Lung
cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
male:female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morita T: A statistical study of lung
cancer in the annual of pathological autopsy cases in Japan, from
1958 to 1997, with reference to time trends of lung cancer in the
world. Jpn J Cancer Res. 93:15–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jackson SP and Bartek J: The DNA-damage
response in human biology and disease. Nature. 461:1071–1078. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Begg AC, Stewart FA and Vens C: Strategies
to improve radiotherapy with targeted drugs. Nat Rev Cancer.
11:239–253. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Barnett GC, West CM, Dunning AM, Elliott
RM, Coles CE, Pharoah PD and Burnet NG: Normal tissue reactions to
radiotherapy: Towards tailoring treatment dose by genotype. Nat Rev
Cancer. 9:134–142. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Osti MF, Agolli L, Valeriani M, Falco T,
Bracci S, De Sanctis V and Enrici RM: Image guided hypofractionated
3-dimensional radiation therapy in patients with inoperable
advanced stage non-small cell lung cancer. Int J Radiat Oncol Biol
Phys. 85:e157–e163. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oshiro Y, Mizumoto M, Okumura T, Hashimoto
T, Fukumitsu N, Ohkawa A, Kanemoto A, Hashii H, Ohno T, Sakae T, et
al: Results of proton beam therapy without concurrent chemotherapy
for patients with unresectable stage III non-small cell lung
cancer. J Thorac Oncol. 7:370–375. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dang CV: MYC on the path to cancer. Cell.
149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dang CV, Le A and Gao P: MYC-induced
cancer cell energy metabolism and therapeutic opportunities. Clin
Cancer Res. 15:6479–6483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen BJ, Wu YL, Tanaka Y and Zhang W:
Small molecules targeting c-Myc oncogene: Promising anti-cancer
therapeutics. Int J Biol Sci. 10:1084–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Riggelen J, Yetil A and Felsher DW:
MYC as a regulator of ribosome biogenesis and protein synthesis.
Nat Rev Cancer. 10:301–309. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ponzielli R, Katz S, Barsyte-Lovejoy D and
Penn LZ: Cancer therapeutics: Targeting the dark side of Myc. Eur J
Cancer. 41:2485–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Meyer N and Penn LZ: Reflecting on 25
years with MYC. Nat Rev Cancer. 8:976–990. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Blander JM: A long-awaited merger of the
pathways mediating host defence and programmed cell death. Nat Rev
Immunol. 14:601–618. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee HO and Ferguson TA: Biology of FasL.
Cytokine Growth Factor Rev. 14:325–335. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Algeciras-Schimnich A, Shen L, Barnhart
BC, Murmann AE, Burkhardt JK and Peter ME: Molecular ordering of
the initial signaling events of CD95. Mol Cell Biol. 22:207–220.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferguson TA and Green DR: Fas-ligand and
immune privilege: The eyes have it. Cell Death Differ. 8:771–772.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang HH, Pang M, Dong W, Xin JX, Li YJ,
Zhang ZC, Yu L, Wang PY, Li BS and Xie SY: miR-511 induces the
apoptosis of radioresistant lung adenocarcinoma cells by triggering
BAX. Oncol Rep. 31:1473–1479. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang PY, Sun YX, Zhang S, Pang M, Zhang
HH, Gao SY, Zhang C, Lv CJ and Xie SY: Let-7c inhibits A549 cell
proliferation through oncogenic TRIB2 related factors. FEBS Lett.
587:2675–2681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gravina GL, Festuccia C, Popov VM, Di
Rocco A, Colapietro A, Sanità P, Monache SD, Musio D, De Felice F,
Di Cesare E, et al: c-Myc sustains transformed phenotype and
promotes radioresistance of embryonal rhabdomyosarcoma cell lines.
Radiat Res. 185:411–422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horton JK, Siamakpour-Reihani S, Lee CT,
Zhou Y, Chen W, Geradts J, Fels DR, Hoang P, Ashcraft KA, Groth J,
et al: FAS death receptor: A breast cancer subtype-specific
radiation response biomarker and potential therapeutic target.
Radiat Res. 184:456–469. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang K, Zhang J, O'Neill KL, Gurumurthy
CB, Quadros RM, Tu Y and Luo X: Cleavage by caspase 8 and
mitochondrial membrane association activate the BH3-only protein
Bid during TRAIL-induced apoptosis. J Biol Chem. 291:11843–11851.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang WJ, Wu SP, Liu JB, Shi YS, Huang X,
Zhang QB and Yao KT: MYC regulation of CHK1 and CHK2 promotes
radioresistance in a stem cell-like population of nasopharyngeal
carcinoma cells. Cancer Res. 73:1219–1231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Larsson LG and Henriksson MA: The Yin and
Yang functions of the Myc oncoprotein in cancer development and as
targets for therapy. Exp Cell Res. 316:1429–1437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chiang CS, Sawyers CL and Mcbride WH:
Oncogene expression and cellular radiation resistance: A modulatory
role for c-myc. Mol Diagn. 3:21–27. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim BY, Kwak SY, Yang JS and Han YH:
Phosphorylation and stabilization of c-Myc by NEMO renders cells
resistant to ionizing radiation through up-regulation of γ-GCS.
Oncol Rep. 26:1587–1593. 2011.PubMed/NCBI
|
|
32
|
Papanikolaou V, Iliopoulos D, Dimou I,
Dubos S, Kappas C, Kitsiou-Tzeli S and Tsezou A: Survivin
regulation by HER2 through NF-κB and c-myc in irradiated breast
cancer cells. J Cell Mol Med. 15:1542–1550. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jung J, Kim EJ, Chung HK, Park HJ, Jeong
SY and Choi EK: c-Myc down-regulation is involved in proteasome
inhibitor-mediated enhancement of radiotherapeutic efficacy in
non-small cell lung cancer. Int J Oncol. 40:385–390.
2012.PubMed/NCBI
|
|
34
|
Danial NN and Korsmeyer SJ: Cell death:
Critical control points. Cell. 116:205–219. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Griffith TS, Brunner T, Fletcher SM, Green
DR and Ferguson TA: Fas ligand-induced apoptosis as a mechanism of
immune privilege. Science. 270:1189–1192. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Peter ME, Legembre P and Barnhart BC: Does
CD95 have tumor promoting activities? Biochim Biophys Acta.
1755:25–36. 2005.PubMed/NCBI
|
|
37
|
Zhang H, Xu Q, Krajewski S, Krajewska M,
Xie Z, Fuess S, Kitada S, Pawlowski K, Godzik A and Reed JC: BAR:
An apoptosis regulator at the intersection of caspases and Bcl-2
family proteins. Proc Natl Acad Sci USA. 97:2597–2602. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaufmann T, Strasser A and Jost PJ: Fas
death receptor signalling: Roles of Bid and XIAP. Cell Death
Differ. 19:42–50. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li H, Zhu H, Xu CJ and Yuan J: Cleavage of
BID by caspase 8 mediates the mitochondrial damage in the Fas
pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Luo X, Budihardjo I, Zou H, Slaughter C
and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome
c release from mitochondria in response to activation of
cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
|
